INTerpath-002

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 11, 2023 → Oct 25, 2026

Cited window

Dec 12, 2023 → Oct 25, 2026

Retrieved

Oct 29, 2026

Title

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)

Registry

NCT06077760

Study IDs

V940-002 · 2023-504923-20-00 (EU CT) · U1111-1290-3969 (UTN) · jRCT2061240063 (jRCT) · PHRR240705-007252 (PHRR)

Sponsor

Merck Sharp & Dohme LLC

Collaborators

ModernaTX, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

868 estimated

Start

2023-12-06 actual

Primary completion

2030-06-25 estimated

Primary endpoint

Disease- Free Survival (DFS)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –50 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, repeated posts and source counts do not establish additional independent clinical voices or consensus.
• –No full protocol, exact-trial results publication or exact product label was available in the reviewed material. The report cannot provide a complete methods, regulatory, efficacy or safety assessment.
• –Melanoma findings, including first impressions of leaked data, are used by contributors as rationale or context. They are not INTerpath-002 outcomes, and uncertainty from the INTerpath-009 residual-disease setting is not a direct assessment of this trial.
• –Some contributors have no confirmed clinical role. Descriptions such as MD or surgical oncologist are attributed source descriptions where noted, not independently confirmed credentials; confirmed personal identity does not increase the certainty of an opinion.
• –Enrollment is described only at the time of the relevant recording, without an identified speaker. It should not be treated as confirmation of current trial status.
• –Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist capacity and access barriers in resectable non-small-cell lung cancer.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "INTerpath-002" (NCT06077760), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "interpath-002-06077760". If you cannot make requests, read https://www.erudio.com/reports/interpath-002-nct06077760.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06077760", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06077760 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/interpath-002-nct06077760.json
curl https://www.erudio.com/reports/interpath-002-nct06077760.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "interpath-002-06077760" })